

# Debora Fumagalli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2705590/publications.pdf>

Version: 2024-02-01

51  
papers

4,098  
citations

218381

26  
h-index

205818

48  
g-index

51  
all docs

51  
docs citations

51  
times ranked

5849  
citing authors

#	ARTICLE	IF	CITATIONS
1	Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. <i>European Journal of Cancer</i> , 2022, 166, 219-228.	1.3	12
2	Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1117-1126.	3.0	3
3	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2021, 22, 212-222.	5.1	169
4	Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer. <i>British Journal of Cancer</i> , 2021, 125, 38-47.	2.9	4
5	70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. <i>Lancet Oncology</i> , The, 2021, 22, 476-488.	5.1	179
6	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. <i>Journal of Clinical Oncology</i> , 2021, 39, 1448-1457.	0.8	171
7	Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D). <i>European Journal of Cancer</i> , 2021, 148, 287-296.	1.3	11
8	Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 2394-2405.	13.9	764
9	Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative. <i>Cancer Discovery</i> , 2021, 11, 2796-2811.	7.7	79
10	Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial. <i>Clinical Cancer Research</i> , 2021, 27, 5607-5618.	3.2	5
11	Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis. <i>Clinical Cancer Research</i> , 2021, 27, 6307-6313.	3.2	8
12	Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa058.	1.4	2
13	Lucitanib for the Treatment of HR+/HER2 <sup>+</sup> Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study. <i>Clinical Cancer Research</i> , 2020, 26, 354-363.	3.2	40
14	Survival outcomes of the NeoALTTO study (BIG 1606): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. <i>European Journal of Cancer</i> , 2019, 118, 169-177.	1.3	51
15	The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. <i>European Journal of Cancer</i> , 2019, 118, 1-9.	1.3	11
16	Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591982771.	1.4	38
17	Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial. <i>Clinical Cancer Research</i> , 2019, 25, 3581-3588.	3.2	73
18	Pharmacokinetic and exploratory exposure-response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 1147-1158.	1.1	8

#	ARTICLE	IF	CITATIONS
19	Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1bâ€² trial. <i>Lancet Oncology</i> , The, 2019, 20, 371-382.	5.1	327
20	Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer. <i>Anti-Cancer Drugs</i> , 2019, 30, 866-872.	0.7	4
21	<sc>Genomic hotspots but few recurrent fusion genes in breast cancer. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 331-338.	1.5	18
22	Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). <i>Breast Cancer Research and Treatment</i> , 2018, 168, 631-638.	1.1	49
23	Feasibility of developing reliable gene expression modules from FFPE derived RNA profiled on Affymetrix arrays. <i>PLoS ONE</i> , 2018, 13, e0203346.	1.1	4
24	Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, e181564.	3.4	13
25	Patient (pt)-reported function and symptoms in APHINITY: A randomized comparison of chemotherapy (C) + trastuzumab (H) + placebo (Pla) versus C + H + pertuzumab (P) as adjuvant therapy in pts with HER2-positive early breast cancer (EBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 521-521.	0.8	5
26	The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data. <i>Clinical Cancer Research</i> , 2017, 23, 2702-2712.	3.2	82
27	RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy. <i>JAMA Oncology</i> , 2017, 3, 227.	3.4	118
28	Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1421-1429.	0.8	116
29	Loss of <i>ARID1A</i> Activates <i>ANXA1</i> , which Serves as a Predictive Biomarker for Trastuzumab Resistance. <i>Clinical Cancer Research</i> , 2016, 22, 5238-5248.	3.2	43
30	Genomic Characterization of Primary Invasive Lobular Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1872-1881.	0.8	249
31	<i>PIK3CA</i> Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2â€“Targeted Therapies in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1334-1339.	0.8	201
32	Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial. <i>Oncotarget</i> , 2015, 6, 30306-30316.	0.8	14
33	New Strategies in Breast Cancer: The Significance of Molecular Subtypes in Systemic Adjuvant Treatment for Small T1a,bN0M0 Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 6242-6246.	3.2	15
34	Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives. <i>Journal of Clinical Oncology</i> , 2014, 32, 2794-2803.	0.8	298
35	Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?. <i>Cancer Treatment Reviews</i> , 2014, 40, 1089-1095.	3.4	30
36	Predicting Degree of Benefit From Adjuvant Trastuzumab in NSABP Trial B-31. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1782-1788.	3.0	94

#	ARTICLE	IF	CITATIONS
37	Somatic Mutation Profiling and Associations With Prognosis and Trastuzumab Benefit in Early Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2013, 105, 960-967.	3.0	138
38	Association between SPARC mRNA Expression, Prognosis and Response to Neoadjuvant Chemotherapy in Early Breast Cancer: A Pooled in-silico Analysis. <i>PLoS ONE</i> , 2013, 8, e62451.	1.1	27
39	Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition. <i>Current Opinion in Oncology</i> , 2012, 24, 623-634.	1.1	44
40	Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value. <i>Clinical Cancer Research</i> , 2012, 18, 6531-6541.	3.2	272
41	A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. <i>Lancet Oncology</i> , The, 2012, 13, e240-e248.	5.1	64
42	Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types. <i>Lancet Oncology</i> , The, 2011, 12, 1162-1168.	5.1	17
43	Unravelling the epigenomic dimension of breast cancers. <i>Current Opinion in Oncology</i> , 2011, 23, 559-565.	1.1	26
44	Integrate: a new model in collaborative breast cancer research. <i>Breast</i> , 2011, 20, S26-S27.	0.9	1
45	Gene Profiling Assay and Application: The Predictive Role in Primary Therapy. <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 124-127.	0.9	9
46	Estrogen Receptor ( <i>ESR1</i> ) mRNA Expression and Benefit From Tamoxifen in the Treatment and Prevention of Estrogen Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4160-4167.	0.8	120
47	Research Highlights. <i>Pharmacogenomics</i> , 2011, 12, 9-13.	0.6	1
48	A time series evaluation of the in vivo effect of letrozole on gene expression in breast cancer. <i>Pharmacogenomics</i> , 2011, 12, 10.	0.6	0
49	Gene-expression changes over time in a tamoxifen-treated breast cancer xenograft model. <i>Pharmacogenomics</i> , 2011, 12, 11.	0.6	0
50	Strategies to Incorporate Translational Research Science into Clinical Trials in Breast Cancer. <i>Current Breast Cancer Reports</i> , 2010, 2, 208-213.	0.5	0
51	Molecular Profiling: Moving Away from Tumor Philately. <i>Science Translational Medicine</i> , 2010, 2, 47ps43.	5.8	71